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Background: The aim of this study was to compare the anti-inflammatory effects of dexamethasone and etori-
coxib after third molar extraction. 
Material and Methods: A prospective, randomized, controlled, split-mouth study was conducted. 19 volunteers 
were allocated randomly to receive 90mg etoricoxib 1 hour prior to the procedure or 4mg intramuscular dexa-
methasone immediately after anesthesia. Baseline measurements were obtained preoperatively, and subsequent 
assessments were made on immediate postoperative, at 72 hours and 7 days after surgery to measure postopera-
tive facial swelling by use of linear measurements, interincisal mouth opening width and visual analog scale score 
for pain. The amount of analgesics consumed was recorded.  Descriptive statistics and the independent-samples 
t-test were used to compare the two groups at P < 0.05. 
Results: Dexamethasone was effective in the control roasted edema for measurements of the mandibular angle 
- wing of the nose and mandibular angle - labial commissure 72 hours after surgery. And for the measurement 
mandibular angle - mentum, in the time of 72 hours and 7 days. There was no statistically significant difference 
in relation to pain and trismus. 
Conclusions: Considering significant results for some measures of the variable edema for the group that used 
intramuscular dexamethasone and the difference without statistical significance between groups for the other vari-
ables studied, we seem to reflect the intramuscular indication of the corticosteroid in a single dosage in relation to 
the use of etoricoxib as pre-emptive medication.
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Introduction
The extraction of mandibular third molars is the most 
frequent intervention in oral surgery (1,2). Although 
performed using a meticulous surgical technique, the 
trauma resulting from this surgery leads to an acute 
inflammatory reaction with considerable pain, swelling 
and trismus (3), which affects quality of life by limiting 
the capacity to perform activities of daily living, espe-
cially in the first three days after surgery (4). Preemp-
tive analgesia has been employed for the management of 
these postoperative symptoms and consists of the phar-
macological modulation of local and systemic media-
tors of pain and inflammation to inhibit the nociceptive 
stimulation resulting from this surgical procedure (4,5). 
Different groups of medication have been employed to 
reduce the postoperative inflammatory response, such 
as steroidal and non-steroidal anti-inflammatory drugs 
(SAIDs and NSAIDs) (1,4-6). 
SAIDs have been used for decades to control inflam-
mation following third molar surgey (3) by inhibiting 
the enzyme phospholipase A2, which is a chemical me-
diator responsible for the induction of arachidonic acid. 
This action results in the reduction of proinflammatory 
mediators, such as prostaglandins, prostacyclins, leu-
kotrienes and thromboxane A2 (1,6). Dexamethasone is 
one of the most widely used SAIDs in third molar sur-
gery due to its predominant glucocorticoid effect, mini-
mal sodium retention activity and long half life (3). En-
teral administration is considered convenient and safe, 
but requires the patient’s cooperation and there may be 
a change in the biological response due to the pharma-
cokinetics of the drug; moreover, there is a late onset ef-
fect in comparison to intramuscular administration (7). 
The injection of corticosteroids in the medial pterygoid 
muscle is acceptable, since this is an area that is anes-
thetized during the operation and this method elimi-
nates the possibility of gastrointestinal side effects (7). 
Another method for preemptive analgesia is the use of 
NSAIDs, which reduce the synthesis of prostaglandins 
derived from arachidonic acid through the inhibition of 
the enzyme cyclooxygenase (COX). Etoricoxib is a se-
lective COX-2 inhibitor that has an analgesic effect for 
the treatment of acute pain, with a fast onset and half 
life of approximately 25 hours (1,8). COX-2-selective 
NSAIDs are associated with fewer gastrointestinal side 
effects, do not affect platelet function and are well tol-
erated. In a study comparing etoricoxib, ibuprofen and 
paracetamol (acetaminophen) combined with codeine 
and placebo, Brown et al. (9) concluded that pain con-
trol was more effective with etoricoxib and ibuprofen 
and that fewer patients in the etoricoxib group required 
rescue medication.
Although previous studies have compared corticoste-
roids and NSAIDs for the control of the symptoms of 
inflammation following third molar surgery, no studies 
have been published comparing dexamethasone ad-
ministered intramuscularly to etoricoxib administered 
orally. Perhaps analgesic efficacies of etoricoxib admin-
istered before extraction of impacted lower third molar 
may be more effective than injection of dexamethasone. 
Therefore, the aim of the present study was to compare 
the anti-inflammatory effects of dexamethasone admin-
istered to the medial pterygoid muscle and etoricoxib 
administered orally following third molar extractions. 
Material and Methods
- Study design
A randomized, double-blind, clinical trial with a split-
mouth design was conducted. The experimental part 
was performed at the university hospital of the Univer-
sidade Federal do Piauí. This study received approval 
from the human research ethics committee of the study 
institution (certificate number: 67695817.6.0000.8050). 
The inclusion criteria were 1) age 18 to 35 years, 2) ab-
sence of systemic disease (ASA I), 3) no use of medi-
cation in the previous seven days, 4) mandibular third 
molars in similar positions with similar root formation 
patterns, 5) absence of allergy to the drugs used in the 
study and 6) surgical site with no current signs or symp-
toms of infection. Patients who met any of the follow-
ing criteria were excluded from the study: 1) pregnancy 
or lactation; 2) history of gastrointestinal bleeding or 
peptic ulcer; 3) allergy to aspirin or NSAIDs; 4) liver, 
kidney, blood or central nervous system disease; 5) con-
tinued use of psychoactive drugs, analgesics, SIADs or 
NSAIDs; and (6) current smoking habit.
Patients were scheduled for surgery in two separate clin-
ical sessions (one side at a time) at least 15 days apart. 
Subjects were allocated to one of two groups through 
a computer-generated randomization code (Microsoft 
Excel) according to the medication received (Group A – 
preoperative administration of 4 mg of dexamethasone 
(Aché, Brazil) in the medial pterygoid muscle immedi-
ately after the administration of anesthesia; Group B – 
preoperative oral administration of 90 mg of etoricoxib 
(DSM, Brazil) one hour prior to surgery).  Information 
on the type of medication provided to each study sub-
ject was withheld from the patient, clinical investiga-
tor (responsible for patient follow-up examinations and 
outcome measurements), and statistician. Prior to sur-
gery, a list containing a randomized distribution of all 
surgical sites and pain medications to be administered 
was held in a sealed envelope by an external study col-
laborator, who was unaware of the study protocol and 
had no further participation in this clinical trial other 
than to guarantee a study design.
To ensure blinding, 1 ml of saline solution was injected 
intramuscularly during the procedure in which etori-
coxib was used and a placebo pill was administered 
one hour prior to surgery during the procedure in which 
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dexamethasone was used. All patients received 12 pills 
of paracetamol 750 mg as the rescue drug to be used as 
deemed necessary for the control of postoperative pain 
and were instructed not to exceed a total of four pills in 
a 24-h period. 
- Calculation of sample size
A pilot study was conducted with eight patients (16 
mandibular third molars) to assist in the calculation of 
the sample size for the main study to enable the statisti-
cal rejection of the null hypothesis with an 80% power 
and 95% confidence interval. The maximum reasonable 
difference between the mean obtained from the sample 
and the true mean of the population was 13. Consider-
ing an α error = 0.05 and seven degrees of freedom a 
sample of 19 patients was determined.
- Surgical procedure
The surgical procedures were performed by a single 
surgeon using a standardized technique in an outpa-
tient setting and all members of the surgical team fol-
lowed biosafety protocols. The same surgical protocol 
was used for both sides to reduce the difference in 
trauma. There was no standardization regarding which 
side would be operated first. The patients received lo-
cal anesthesia with 2% mepivacaine and epinephrine 
1:200.000. The muco-periosteal flap was detached, fol-
lowed by ostectomy and tooth sectioning under irriga-
tion with saline solution. After smoothing the bone edg-
es, the surgical wound was irrigated abundantly with 
0.9% saline solution and the suture was performed with 
nylon 4-0 thread (Ethicon). 
- Assessment methods
Postoperative facial swelling was assessed using five 
measurements described by Neupert et al., (10): 1- angle 
of the mandible/tragus, 2- angle of the mandible/corner 
of the eye; 3- angle of the mandible/ala of the nose; 4- 
angle of the mandible/lip commissue and 5- angle of 
the mandible/pogonion (Fig. 1). The preoperative val-
ues were compared to those determined immediately 
after surgery, 72 hours after surgery and seven days af-
ter surgery. Trismus was measured as the difference in 
maximal mouth opening. This procedure was repeated 
immediately after surgery, 72 hours after surgery and 
seven days after surgery.
Postoperative pain was determined using the Visual 
Analog Scale (VAS), 10-cm long, that ranged from 
0 (absence of pain) to 10 (maximum pain) (3-5). The 
amount of the rescue drug used and time of surgery 
(from the beginning of the incision to the end of the su-
ture) was also recorded.
- Data analysis 
Central tendency (mean and standard deviation) and 
dispersion (minimum and maximum) measures were 
used. For the quantitative variables, the Shapiro-Wilk 
test was used to determine adherence to normal distri-
bution. The Student’s t-test for paired samples and Wil-
coxon test were used for the comparisons of the groups 
(edema measurements, total and mean number of anal-
gesics taken in postoperative period). Pearson’s correla-
tion coefficients were calculated to determine correla-
tions between parametric variables (correlation of pain 
with number of analgesics) and Spearman’s correlation 
coefficients were calculated to determine correlations 
between nonparametric variables (correlation of trismus 
with over time). The data were tabulated electronically 
using Microsoft Office Excel and analyzed with the aid 
of the IBM Statistical Package for the Social Sciences 
(SPSS version 20.0).
Fig. 1: Measurement of swelling.
Table 1: Characteristics of patients.






Age 24.3 ± 4.6 18 – 32
Surgical 
time
etoricoxib 26.5 ± 




4.2 20 – 33
SD – standard desviation; Min – minimum; Max - maximum.
Results
Nineteen individuals (11 women and eight men) were 
recruited between September 2017 and March 2018 and 
adhered to the study protocol. Age ranged from 18 to 
32 years (mean: 23.73 years). No statistically significant 
differences in surgery time were found between the dif-
ferent treatments (Table 1). 
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In the comparison of the edema between groups A and 
B, it was possible to observe that there was no statisti-
cally significant difference for 1 and 2 measurements 
between evaluation times (t-test; Wilcoxon test). Statis-
tically significant differences were found in the 3 and 
4 measurements between the preoperative evaluation 
and 72-hour evaluation. Significant differences for the 5 
measurement were found at both the 72-hour and seven-
day evaluations (Table 2).
Table 2: Facial measurements at pre-operative, immediate post-op-




Drug Pre-Op Post-Op 72h 7days
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7,4 97,7 ± 7,6 95,2 ± 6,9
p-value 0,975a 0,796a 0,695b 0,541b
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p-value 0,162a 0,181a 0,039a 0,137a
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8,9 79,9 ± 8,3
p-value 0,226a 0,238a 0,034a 0,316a
5 

















p-value 0,061a 0,123b 0,003a 0,028b
SD – standard desviation; a t-test; b Wilcoxon test; p-value = 0.05.
Mean postoperative pain was higher in the dexametha-
sone group, but the difference was not statistically sig-
nificant (Fig. 2). Trismus 72 hours after surgery was 
worse in the etoricoxib group, but the difference did not 
achieve statistical significance (Fig. 3). No significant 
difference between groups was found in the number 
of rescue drugs taken (Table 3). A positive correlation 
was found between pain intensity and number of rescue 
drugs taken (p < 0.05) (Table 4).
Analgesics Sum mean ± SD p-value
Etoricoxib 30 1.6 ± 1.3 0.634
Dexamethasone 27 1.4 ± 1.6  
SD – standard desviation; Wilcoxon test.








r – relation; a Spearman’s correlation;b Pearson’s  correlation.
Fig. 2: Mean pain intensity at pre-operative, immediate post-opera-
tive, 72-hour and seven-day evaluations.
Fig. 3: Boxplot of trismus at pre-operative, immediate post-opera-
tive, 72-hour and seven-day evaluations.
Table 3: Total and mean number of analgesics taken in postopera-
tive period.
Table 4: Correlation matrix of pain with number of analgesics and 
trismus over time.
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Discussion
Excessive swelling, pain and trismus are often associ-
ated with this type of surgery, (3,11,12) the intensity of 
which varies with the extent of the trauma, which is di-
rectly related to the degree of surgical difficulty. The 
dental pain model used after third molar surgeries is one 
of the most common and widely accepted for the evalu-
ation of analgesics in humans (1,13). Anti-inflammatory 
agents have been used preemptively to reduce the in-
flammatory signs and symptoms resulting from this 
surgical procedure (4,5). The present study evaluated 
the effectiveness of an NSAID administered orally and 
a corticosteroid administered intramuscularly, which 
are widely used classes of drugs in third molar extrac-
tions (4,14). 
Levels of postoperative pain depend on the tissue trauma 
caused by the surgical procedure (2-5,15-17). In a previ-
ous study, mean pain scores were lower in the group 
that made use of dexamethasone in comparison to the 
control group at all evaluation times (2). However, there 
is no consensus on the role of corticosteroids in the con-
trol of  postoperative pain. While some researchers state 
that corticosteroids alone have no significant analgesic 
effect, (6,18) others found that the use of SAIDs led to 
reductions in mean pain following third molar extrac-
tions (2,3,11). In a clinical trial conducted by Costa et 
al. (4), peak postoperative pain occurred six hours after 
the procedure in patients medicated with etoricoxib and 
mean postoperative pain scores were significantly lower 
in these patients. One of the limitations of the present 
study was the cooperation of the patients in filling out 
the VAS charts, which compromised the assessment 
of pain in the first 48 hours after surgery. Therefore, 
the analysis of this variable was only performed on the 
third day, when the patients returned for the evaluations 
of swelling and trismus. Lower mean pain scores were 
found when the patients took etoricoxib, but the differ-
ence compared to dexamethasone was non-significant.
In the present study, the method described by Neupert 
et al. (13) was used. Costa et al. (4) analyzed the pre-
emptive effect of etoricoxib (120 mg) and placebo on in-
flammatory events after the removal of third molars and 
found no significant difference in facial measurements 
between groups at any evaluation time. Sotto-Maior et 
al. (1) compared the anti-inflammatory effects of etori-
coxib (120 mg) and dexamethasone (4 mg) adminis-
tered orally one hour prior to the procedure and found 
no significant differences in postoperative swelling. In 
contrast, dexamethasone was more effective at control-
ling edema regarding the 3 and 4 measurements after 72 
hours as well as the 5 measurement after 72 hours and 
seven days in the present investigation. Mojsa et al. (19) 
evaluated the submucosal injection of dexamethasone 
and found that peak swelling in patients who received 
placebo occurred on the third day and these patients had 
significantly larger facial measurements. Antunes et al. 
(20) compared the administration of dexamethasone in-
tramuscularly (masseter muscle), orally and a placebo 
and found that the control group had the greatest swell-
ing. Moreover, the patients who received oral dexa-
methasone had greater swelling values in comparison to 
those who received the medication intramuscularly, but 
the difference did not achieved statistical significance. 
These findings suggest that the parenteral administra-
tion of dexamethasone achieves better results due to its 
faster onset in comparison to enteral administration.
Moore et al. (21) found that trismus was more severe in 
all treatment groups on the first or second day after sur-
gery and returned to normal beginning on the seventh 
day. Majid (22) compared the effects of dexamethasone 
administered through submucosal and intramuscular 
routes and found a greater occurrence of trismus in the 
first postoperative day, with no significant difference 
between the patients submitted to different the admin-
istration routes. Similarly to the findings cited above, 
no significant different in trismus was found between 
the groups in the present investigation. In a systematic 
review, Almeida et al. (23) found that the preemptive 
administration of corticosteroids achieved better re-
sults regarding the control of trismus, which may be 
explained by the fact that the drug is made available 
to the organism prior to the tissue injury. According to 
Alexander and Throndson (18), to obtain the maximum 
expected benefit from the preemptive use of corticoste-
roids, administration should be performed two to four 
hours prior to the procedure to obtain adequate tissue 
levels.
The use of rescue medication adds an additional vari-
able to the research design. da Costa Araújo et al. (12) 
state that the use of analgesics in the postoperative pe-
riod is the most difficult aspect to control in a study due 
to the difficulty in establishing a standardized method 
that guides the use of these medications on the part of 
patients and may lead to overestimation of the beneficial 
effect of the group that took more rescue medication, in-
creased risk of bias. In an attempt to compensate for this 
risk of bias, a comparison was made of the amount of 
rescue medication used in both groups. No statistically 
significant difference was found in the mean number 
of analgesics used in each group (1.6 in the etoricoxib 
group and 1.4 in the dexamethasone). The present find-
ings differ from those described by Costa et al. (4), who 
found that the mean number of capsules of the rescue 
drug consumed in the first 24 hours and total amount 
rescue drug consumed was significantly lower in the 
group that received etoricoxib, which led to a signifi-
cant reduction in postoperative pain and the need for the 
rescue drug. Sotto-Maior et al. (1) compared the anti-
inflammatory effects of etoricoxib (120 mg) and dexa-
methasone (4 mg) administered one hour prior to the 
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procedure and found no statistically significant differ-
ence in the amount of rescue drug used, which is similar 
to the findings described in the present study.
The drugs evaluated (dexamethasone and etoricoxib) in 
the respective doses and administration routes achieved 
similar effectiveness with regard to controlling pain 
and trismus following the extraction of mandibular 
third molars. Moreover, dexamethasone achieved better 
results with regard to the control of swelling for the 3 
and 4 measurements at 72 hours as well as the 5 mea-
surement at both 72 hours and seven days after surgery. 
Within the limitations of the study, the intramuscular 
administration of this corticoid in a single dose is sug-
gested rather than the use of etoricoxib as a preemptive 
strategy in third molar surgeries.
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